Uprima Bibliography

1: Martinez R, Puigvert A, Pomerol JM, Rodriguez-Villalba R. 
Clinical experience with apomorphine hydrochloride: the first 107 patients.
J Urol. 2003 Dec;170(6 Pt 1):2352-5. 
14634414 

2: DasGupta R, Fowler CJ. 
Bladder, bowel and sexual dysfunction in multiple sclerosis: management
strategies.
Drugs. 2003;63(2):153-66. Review. 
12515563 

3: Bayes M, Rabasseda X, Prous JR. 
Gateways to clinical trials.
Methods Find Exp Clin Pharmacol. 2002 Oct;24(8):525-51. 
12500432 

4: Ichise J, Yokokawa K. 
[Preclinical studies of apomorphine hydrochloride]
Nippon Rinsho. 2002 Jun;60 Suppl 6:452-6. Review. Japanese. No abstract
available. 
12166199 

5: Bayes M, Rabasseda X, Prous JR. 
Gateways to clinical trials.
Methods Find Exp Clin Pharmacol. 2002 May;24(4):217-48. Review. 
12092009 

6: Lammers PI, Rubio-Aurioles E, Castell R, Castaneda J, Ponce de Leon R,
Hurley D, Lipezker M, Loehr LA, Lowrey F. 
Combination therapy for erectile dysfunction: a randomized, double blind,
unblinded active-controlled, cross-over study of the pharmacodynamics and safety
of combined oral formulations of apomorphine hydrochloride, phentolamine
mesylate and papaverine hydrochloride in men with moderate to severe erectile
dysfunction.
Int J Impot Res. 2002 Feb;14(1):54-9; discussion 60. 
11896479 

7: Dewey RB Jr, Hutton JT, LeWitt PA, Factor SA. 
A randomized, double-blind, placebo-controlled trial of subcutaneously injected
apomorphine for parkinsonian off-state events.
Arch Neurol. 2001 Sep;58(9):1385-92. 
11559309 

8: Peira E, Scolari P, Gasco MR. 
Transdermal permeation of apomorphine through hairless mouse skin from
microemulsions.
Int J Pharm. 2001 Sep 11;226(1-2):47-51. 
11532569 

9: Ng Ying Kin NM, Lal S, Thavundayil JX. 
Stability of apomorphine hydrochloride in aqueous sodium bisulphite solutions.
Prog Neuropsychopharmacol Biol Psychiatry. 2001 Oct;25(7):1461-8. 
11513359 

10: Friess E, Kuempfel T, Winkelmann J, Schmid D, Uhr M, Rupprecht R, Holsboer
F, Trenkwalder C. 
Increased growth hormone response to apomorphine in Parkinson disease compared
with multiple system atrophy.
Arch Neurol. 2001 Feb;58(2):241-6. 
11176962 

11: [No authors listed] 
Apomorphine (TAP holdings). 6a beta-aporphine-10,11-diol hydrochloride
hemihydrate, apomorphine hydrochloride, spontane, Uprima.
Drugs R D. 1999 Dec;2(6):415-6. No abstract available. 
10763454 

12: Ondo W, Hunter C, Almaguer M, Jankovic J. 
A novel sublingual apomorphine treatment for patients with fluctuating
Parkinson's disease.
Mov Disord. 1999 Jul;14(4):664-8. 
10435505 

13: Chen KK, Chan JY, Chang LS. 
Dopaminergic neurotransmission at the paraventricular nucleus of hypothalamus
in central regulation of penile erection in the rat.
J Urol. 1999 Jul;162(1):237-42. 
10379793 

14: Ondo W, Hunter C, Almaguer M, Gancher S, Jankovic J. 
Efficacy and tolerability of a novel sublingual apomorphine preparation in
patients with fluctuating Parkinson's disease.
Clin Neuropharmacol. 1999 Jan-Feb;22(1):1-4. 
10047926 

15: Kuno S, Mizuta E, Sakamoto H, Ichihara K, Nagasaka M. 
Antiparkinsonian effects of BAM-1110, a novel ergoline derivative, in
MPTP-treated cynomolgus monkeys.
Clin Neuropharmacol. 1998 Jan-Feb;21(1):35-40. 
9579283 

16: Druhan JP, Rajabi H, Stewart J. 
MK-801 increases locomotor activity without elevating extracellular dopamine
levels in the nucleus accumbens.
Synapse. 1996 Oct;24(2):135-46. 
8890455 

17: Ichikawa J, Meltzer HY. 
DOI, a 5-HT2A/2C receptor agonist, potentiates amphetamine-induced dopamine
release in rat striatum.
Brain Res. 1995 Nov 6;698(1-2):204-8. 
8581482 

18: Schafe GE, Sollars SI, Bernstein IL. 
The CS-US interval and taste aversion learning: a brief look.
Behav Neurosci. 1995 Aug;109(4):799-802. 
7576224 

19: Roth J, Ruzicka E, Mecir P. 
[The apomorphine test in the differential diagnosis of Parkinsonism. Initial
experience]
Cas Lek Cesk. 1994 Nov 7;133(21):665-7. Czech. 
7805088 

20: Allison K, Paetsch PR, Baker GB, Greenshaw AJ. 
Chronic antidepressant drug treatment attenuates motor-suppressant effects of
apomorphine without changing [3H]GBR 12935 binding.
Eur J Pharmacol. 1993 Nov 9;249(2):125-31. 
8287894 

21: Mauguiere F, Broussolle E, Isnard J. 
Apomorphine-induced relief of the akinetic-rigid syndrome and early median
nerve somatosensory evoked potentials (SEPs) in Parkinson's disease.
Electroencephalogr Clin Neurophysiol. 1993 Jul-Aug;88(4):243-54. 
7688279 

22: Lieberman JA, Jody D, Alvir JM, Ashtari M, Levy DL, Bogerts B, Degreef G,
Mayerhoff DI, Cooper T. 
Brain morphology, dopamine, and eye-tracking abnormalities in first-episode
schizophrenia. Prevalence and clinical correlates.
Arch Gen Psychiatry. 1993 May;50(5):357-68. 
8489325 

23: Gasser T, Schwarz J, Arnold G, Trenkwalder C, Oertel WH. 
Apomorphine test for dopaminergic responsiveness in patients with previously
untreated Parkinson's disease.
Arch Neurol. 1992 Nov;49(11):1131-4. 
1444878 

24: Fukamauchi F, Yoshikawa T, Shibuya H. 
Pre-synaptic dopaminergic control mechanisms for CCK-8 like immunoreactivity in
the rat medial frontal cortex.
Neuropeptides. 1992 Oct;23(2):55-9. 
1360636 

25: Jones GH, Hernandez TD, Kendall DA, Marsden CA, Robbins TW. 
Dopaminergic and serotonergic function following isolation rearing in rats:
study of behavioural responses and postmortem and in vivo neurochemistry.
Pharmacol Biochem Behav. 1992 Sep;43(1):17-35. 
1384071 

26: Rascol O, Sabatini U, Chollet F, Celsis P, Montastruc JL, Marc-Vergnes JP,
Rascol A. 
Supplementary and primary sensory motor area activity in Parkinson's disease.
Regional cerebral blood flow changes during finger movements and effects of
apomorphine.
Arch Neurol. 1992 Feb;49(2):144-8. 
1736846 

27: Segraves RT, Bari M, Segraves K, Spirnak P. 
Effect of apomorphine on penile tumescence in men with psychogenic impotence.
J Urol. 1991 Jun;145(6):1174-5. 
2033687 

28: Blin O, Azulay JP, Masson G, Aubrespy G, Serratrice G. 
Apomorphine-induced yawning in migraine patients: enhanced responsiveness.
Clin Neuropharmacol. 1991 Feb;14(1):91-5. 
2029696 

29: Naitoh T, Imamura M, Wassersug RJ. 
Interspecific variation in the emetic response of anurans.
Comp Biochem Physiol C. 1991;100(3):353-9. 
1687529 

30: Blin O, Masson G, Azulay JP, Fondarai J, Serratrice G. 
Apomorphine-induced blinking and yawning in healthy volunteers.
Br J Clin Pharmacol. 1990 Nov;30(5):769-73. 
2271377 

31: Elphick M, Yang JD, Cowen PJ. 
Effects of carbamazepine on dopamine- and serotonin-mediated neuroendocrine
responses.
Arch Gen Psychiatry. 1990 Feb;47(2):135-40. 
2105705 

32: Brown GM, Cleghorn JM, Kaplan RD, Szechtman H, Brown PJ, Szechtman B,
Mitton J. 
Longitudinal growth hormone studies in schizophrenia.
Psychiatry Res. 1988 May;24(2):123-36. 
3406233 

33: Szechtman H, Cleghorn JM, Brown GM, Kaplan RD, Franco S, Rosenthal K. 
Sensitization and tolerance to apomorphine in men: yawning, growth hormone,
nausea, and hyperthermia.
Psychiatry Res. 1988 Mar;23(3):245-55. 
3387500 

34: Goodwin GM, Fairburn CG, Cowen PJ. 
The effects of dieting and weight loss on neuroendocrine responses to
tryptophan, clonidine, and apomorphine in volunteers. Important implications for
neuroendocrine investigations in depression.
Arch Gen Psychiatry. 1987 Nov;44(11):952-7. 
3675135 

35: Ueno S, Matsuki N, Saito H. 
Suncus murinus: a new experimental model in emesis research.
Life Sci. 1987 Jul 27;41(4):513-8. 
3600192 

36: Zemlan FP, Hirschowitz J, Garver DL. 
Relation of clinical symptoms to apomorphine-stimulated growth hormone release
in mood-incongruent psychotic patients.
Arch Gen Psychiatry. 1986 Dec;43(12):1162-7. 
3778112 

37: Bianchi G, Landi M, Garattini S. 
Disposition of apomorphine in rat brain areas: relationship to stereotypy.
Eur J Pharmacol. 1986 Nov 19;131(2-3):229-36. 
3816953 

38: Mattingly BA. 
The effects of apomorphine on leverpress shock escape learning in rats.
Pharmacol Biochem Behav. 1986 Sep;25(3):693-5. 
3774836 

39: Davis AS, Jenner P, Marsden CD. 
A comparison of motor behaviours in groups of rats distinguished by their
climbing response to apomorphine.
Br J Pharmacol. 1986 Jan;87(1):129-37. 
3955297 

40: Gottschall PE, Meites J. 
Evidence for a permanent decline in tuberoinfundibular dopaminergic neuronal
function after chronic estrogen treatment is terminated in Fischer 344 rats.
Neuroendocrinology. 1986;44(2):211-6. 
3796794 

41: Davis BM, Davis KL, Mohs RC, Mathe AA, Rothpearl AB, Johns CA, Levy MI,
Horvath TB. 
Evaluating prolactin response to dopamine agonists in schizophrenia.
Methodological problems.
Arch Gen Psychiatry. 1985 Mar;42(3):259-64. 
3977547 

42: Whalley LJ, Christie JE, Brown S, Arbuthnott GW. 
Schneider's first-rank symptoms of schizophrenia. An association with increased
growth hormone response to apomorphine.
Arch Gen Psychiatry. 1984 Nov;41(11):1040-3. 
6497565 

43: Meltzer HY, Kolakowska T, Fang VS, Fogg L, Robertson A, Lewine R,
Strahilevitz M, Busch D. 
Growth hormone and prolactin response to apomorphine in schizophrenia and the
major affective disorders. Relation to duration of illness and depressive
symptoms.
Arch Gen Psychiatry. 1984 May;41(5):512-9. 
6721674 

44: Turski L, Schwarz M, Sontag KH. 
Stereotypy, locomotor and cataleptic effects produced by drugs influencing
dopaminergic systems in a mutant strain of Wistar rats: a genuine model of basal
ganglia dysfunction?
Behav Brain Res. 1984 Apr;12(1):29-37. 
6539616 

45: Cheal M, Kurkulos ME, Silva L. 
Implications for multiple transmitter mediation of amphetamine-induced
stereotypies.
Pharmacol Biochem Behav. 1982 Dec;17(6):1305-8. 
6891794 

46: Rieke GK. 
The TPc, the avian substantia nigra: pharmacology and behavior.
Physiol Behav. 1982 May;28(5):755-63. 
7100277 

47: Brass CA, Glick SD. 
Sex differences in drug-induced rotation in two strains of rats.
Brain Res. 1981 Oct 26;223(1):229-34. 
7284807 

48: Decker WJ, Corby DG, Combs HF. 
A stable parenteral solution of apomorphine.
Clin Toxicol. 1981 Jul;18(7):763-72. 
7307461 

49: Watanabe H, Nakano S, Ogawa N. 
Pharmacokinetic study of apomorphine-induced stereotypy in food deprived rats.
Pharmacol Biochem Behav. 1981 Apr;14(4):493-6. 
7195038 

50: Gorewit RC. 
Effect of apomorphine hydrochloride administration on serum concentrations of
prolactin and growth hormone in cattle.
Experientia. 1981 Feb 15;37(2):204-6. No abstract available. 
7238762 

51: Savageau MM, Beatty WW. 
Gonadectomy and sex differences in the behavioral responses to amphetamine and
apomorphine of rats.
Pharmacol Biochem Behav. 1981 Jan;14(1):17-21. 
7193328 

52: Wilcox RE, Humphrey DW, Riffee WH, Smith RV. 
Stability of apomorphine in solutions containing ascorbic acid and bisulfite
and effects of antioxidants on apomorphine-induced cage climbing and hypothermia
in mice.
J Pharm Sci. 1980 Aug;69(8):974-6. 
7400950 

53: Nakano S, Hara C, Ogawa N. 
Circadian rhythm of apomorphine-induced stereotypy in rats.
Pharmacol Biochem Behav. 1980 Mar;12(3):459-61. 
7190288 

54: Cervantes A, Cervantes P, Correu S, Velasco V. 
[Secretion of growth hormone in men and women during the reproductive age, in
aged men and menopausal women with or without estrogens or progesterone]
Ginecol Obstet Mex. 1979 Mar;45(269):185-98. Spanish. 
540766 

55: Jenner P, Pycock C, Marsden CD. 
The effect of chronic administration and withdrawal of amphetamine on cerebral
dopamine receptor sensitivity.
Psychopharmacology (Berl). 1978 Jul 6;58(2):131-6. 
98779 

56: Tolosa ES. 
Midification of tardive dyskinesia and spasmodic torticollis by apomorphine.
Possible role of dopamine autoreceptors.
Arch Neurol. 1978 Jul;35(7):459-62. 
666598 

57: de Lanerolle NC, Youngren OM. 
Chick vocalization and emotional behavior influenced by apomorphine.
J Comp Physiol Psychol. 1978 Jun;92(3):416-30. 
681562 

58: Corsini GU, Onali P, Masala C, Cianchetti C, Mangoni A, Gessa G. 
Apomorphine hydrochloride-induced improvement in Huntington's chorea:
stimulation of dopamine receptor.
Arch Neurol. 1978 Jan;35(1):27-30. 
145840 

59: Kiefer SW, Braun JJ. 
Absence of differential associative responses to novel and familiar taste
stimuli in rats lacking gustatory neocortex.
J Comp Physiol Psychol. 1977 Jun;91(3):498-507. 
874118 

60: Kartzinel R, Hunt RD, Calne DB. 
Bromocriptine in Huntington chorea.
Arch Neurol. 1976 Jul;33(7):517-8. 
132915 

61: Cox B, Ary M, Lomax P. 
Changes in sensitivity to apomorphine during morphine dependence and withdrawal
in rats.
J Pharmacol Exp Ther. 1976 Mar;196(3):637-41. 
944260 

62: Suprun PP. 
[Iodometric methods for the quantitative determination of apomorphine
hydrochloride]
Farm Zh. 1976 Mar-Apr;(2):57-62. Ukrainian. No abstract available. 
5291 

63: Tang LC, Cotzias GC. 
Modification of the actions of some neuroactive drugs by growth hormone.
Arch Neurol. 1976 Feb;33(2):131-4. 
1252146 

64: Nilsson KO. 
Lack of effect of hyperglycaemia on apomorphine induced growth hormone release
in normal man.
Acta Endocrinol (Copenh). 1975 Oct;80(2):230-6. 
1242266 

65: Horowski R, Neumann F, Graf KJ. 
Influence of apomorphine hydrochloride, dibutyryl-apomorphine and Lysenyl on
plasma prolactin concentrations in the rat.
J Pharm Pharmacol. 1975 Jul;27(7):532-4. No abstract available. 
239161 

66: Meldrum B, Anlezark G, Trimble M. 
Drugs modifying dopaminergic activity and behaviour, the EEG and epilepsy in
Papio papio.
Eur J Pharmacol. 1975 Jun-Jul;32(02):203-13. 
1149807 

67: Klawans HL, Margolin DI. 
Amphetamine-induced dopaminergic hypersensitivity in guinea pigs. Implications
in psychosis and human movement disorders.
Arch Gen Psychiatry. 1975 Jun;32(6):725-32. 
1130936 

68: Lal S, Martin JB, De la Vega CE, Friesen HG. 
Comparison of the effect of apomorphine and L-DOPA on serum growth hormone
levels in normal men.
Clin Endocrinol (Oxf). 1975 May;4(3):277-85. 
1149303 

69: Lundgren P, Landersjo L. 
Stability and stabilization of apomorphine hydrochloride in aqueous solution.
Acta Pharm Suec. 1970 Apr;7(2):133-48. No abstract available. 
5421620 

70: LECOQ R. 
[Comparison of the usual doses of apomorphine hydrochloride used in therapy
with the maximum doses prescribed in the pharmacopeia]
Ann Pharm Fr. 1953 Mar;11(3):203-8. Undetermined Language. No abstract
available. 
13058231